NCT00240747终止3 期
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Pfizer
- 试验地点
- 11
- 主要终点
- Population pharmacokinetics
研究概览
简要总结
Open-label, multicenter, multiple-dose, study of population pharmacokinetics of I.V. Synercid (7.5 mg/kg every 8 hours) in 75 pediatric patients. The purpose is to assess the population pharmacokinetics of Synercid in pediatric patients and to collect additional safety and efficacy data in pediatric patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 27 Weeks 至 16 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Serious, suspected or documented gram-positive infection
排除标准
- 未提供
结局指标
主要结局
Population pharmacokinetics
次要结局
- Safety
- Efficacy
研究者
研究点 (11)
Loading locations...
相似试验
进行中（未招募）
3 期
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency DiseasesPrimary Immune DeficiencyNCT04640142Octapharma50
已完成
1 期
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric PatientsHematological MalignancyNCT03241550Astellas Pharma Global Development, Inc.49
已完成
1 期
A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.HealthyNCT04081844Hanmi Pharmaceutical Company Limited31
已完成
3 期
Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan ProcedureThrombosisNCT02846532Janssen Research & Development, LLC112
Unknown
1 期
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid TumorSolid TumorNCT04802980Huabo Biopharm Co., Ltd.72